These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32052515)

  • 1. Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'.
    Goadsby PJ; Terwindt GM; Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK
    Eur J Neurol; 2020 May; 27(5):e25. PubMed ID: 32052515
    [No Abstract]   [Full Text] [Related]  

  • 2. Do different treatment strategies of galcanezumab have a similar effect on migraine?
    Huang IH; Wu PC; Lee YH; Kang YN
    Eur J Neurol; 2020 Apr; 27(4):e19-e20. PubMed ID: 31846550
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
    Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.
    Martinez JM; Hindiyeh N; Anglin G; Kalidas K; Hodsdon ME; Kielbasa W; Moser BA; Pearlman EM; Garces S
    Cephalalgia; 2020 Aug; 40(9):978-989. PubMed ID: 32340471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.
    Oakes TMM; Skljarevski V; Zhang Q; Kielbasa W; Hodsdon ME; Detke HC; Camporeale A; Saper JR
    Cephalalgia; 2018 May; 38(6):1015-1025. PubMed ID: 29310444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
    Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
    Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
    Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
    Kielbasa W; Helton DL
    Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
    Ossipov MH; Raffa RB; Pergolizzi JV
    Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment efficacy of galcanezumab for migraine: A meta-analysis of randomized controlled trials.
    Ren Z; Zhang H; Wang R; Yuan Q; Pan L; Chen C
    Clin Neurol Neurosurg; 2019 Nov; 186():105428. PubMed ID: 31581028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.
    Förderreuther S; Zhang Q; Stauffer VL; Aurora SK; Láinez MJA
    J Headache Pain; 2018 Dec; 19(1):121. PubMed ID: 30594122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
    Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
    JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
    Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
    Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galcanezumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Nov; 78(16):1769-1775. PubMed ID: 30378008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.